BioCentury | Apr 27, 2017
Clinical News

CYC140: Preclinical data

...In mouse xenograft models of esophageal cancer and acute leukemia, CYC140 significantly reduced mean tumor volume...
...controls. Data were presented at the American Association for Cancer Research meeting in Washington, D.C. CYC140...
...inhibitor. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Product: CYC140 Business: Cancer Indication: Treat cancer Alicia Parker CYC140 Cyclacel...
BioCentury | Mar 18, 2013
Finance

U.K. cash catalyst

...domiciled in the U.K. The £1.9 million ($2.8 million) award will fund preclinical development of CYC140...
Items per page:
1 - 2 of 2